As indicated earlier, however, conjugating DYRK1A inhibitors to a beta cell-specific targeting molecule may actually be undesirable, depriving them of beneficial effects on autoimmunity and/or adipocytes. The gene discussed is DYRK1A; the disease is Autoimmunity.